ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
VolitionRX Limited

VolitionRX Limited (VNRX)

0.73
0.02
(2.82%)
Closed July 23 4:00PM
0.7003
-0.0297
(-4.07%)
After Hours: 6:49PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.7003
Bid
-
Ask
-
Volume
144,018
0.68 Day's Range 0.738199
0.55 52 Week Range 1.53
Market Cap
Previous Close
0.71
Open
0.6851
Last Trade
698
@
0.73
Last Trade Time
Financial Volume
$ 103,820
VWAP
0.720881
Average Volume (3m)
109,655
Shares Outstanding
82,815,121
Dividend Yield
-
PE Ratio
-1.71
Earnings Per Share (EPS)
-0.43
Revenue
775k
Net Profit
-35.32M

About VolitionRX Limited

VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed ... VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy. Show more

Sector
In Vitro,in Vivo Diagnostics
Industry
Mng, Quarry Nonmtl Minerals
Headquarters
Wilmington, Delaware, USA
Founded
2012
VolitionRX Limited is listed in the In Vitro,in Vivo Diagnostics sector of the American Stock Exchange with ticker VNRX. The last closing price for VolitionRX was $0.71. Over the last year, VolitionRX shares have traded in a share price range of $ 0.55 to $ 1.53.

VolitionRX currently has 82,815,121 shares outstanding. The market capitalization of VolitionRX is $58.80 million. VolitionRX has a price to earnings ratio (PE ratio) of -1.71.

VNRX Latest News

Volition appoints PharmaVentures for Capture PCRβ„’ and oncology portfolio licensing

Volition appoints PharmaVentures for Capture PCRβ„’ and oncology portfolio licensing PR Newswire HENDERSON, Nev., July 9, 2024 HENDERSON, Nev., July 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE...

VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting

VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting PR Newswire HENDERSON, Nev., June 27, 2024 HENDERSON, Nev., June 27, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.05438.405572755420.6460.7381990.631405830.6596567CS
40.05037.738461538460.650.7381990.60481145160.6353743CS
12-0.1935-21.64913850970.89380.950.60481096550.71525078CS
26-0.2897-29.26262626260.991.230.571452400.81182739CS
52-0.7797-52.68243243241.481.530.551792030.87010761CS
156-2.3897-77.33656957933.094.14010.551348501.70374341CS
260-2.8997-80.54722222223.67.690.551909743.02357321CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
158.15M
CMAXCareMax Inc
$ 5.19
(228.48%)
102.64M
NUKKNukkleus Inc
$ 0.499
(55.94%)
26.2M
SNOASonoma Pharmaceuticals Inc
$ 0.423
(37.34%)
4.88M
ONDSOndas Holdings Inc
$ 1.1297
(34.06%)
2.19M
CGBSCrown LNG Holdings Ltd
$ 0.9902
(-29.77%)
3.29M
LGCBLinkage Global Inc
$ 3.7833
(-27.45%)
166.7k
SPECSpectaire Holdings Inc
$ 0.395
(-24.76%)
1.78M
GSUNGolden Sun Health Technology Group Ltd
$ 5.07
(-24.55%)
155.37k
SLNASelina Hospitality PLC
$ 0.0364
(-23.04%)
75.77M
NVDANVIDIA Corporation
$ 123.45
(4.68%)
221.22M
SQQQProShares UltraPro Short QQQ
$ 8.08
(-4.49%)
176.65M
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
151.42M
SERVServe Robotics Inc
$ 8.7192
(15.49%)
148.59M
NCPLNetcapital Inc
$ 0.1105
(6.25%)
121.97M

VNRX Discussion

View Posts
Rayn_Makr Rayn_Makr 2 weeks ago
215,000 shares traded on7/9/2024 at 11;25 @ $0.60. Lately its been 20,000 a day. I think somebody knows something is up. TWT.
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
VNRX under $2
πŸ‘οΈ0
Agoura Guy Agoura Guy 6 months ago
BEWARE OF THE STOCK PUMPING CRIMINAL WHO SHORTS HIS OWN PUMPS!!!!!!!

CHECK OUT HIS POSTING HISTORY!!!!!!!


👍️ 1 🚫 1
TrendTrade2016 TrendTrade2016 6 months ago
VNRX...NEW BIO PLAY UNDERWAY WITH A 1.32 TRIGGER UP A HEAD!!!
πŸ‘οΈ0
glenn1919 glenn1919 6 months ago
VNRX.......................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 6 months ago
VNRX.............................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
glenn1919 glenn1919 9 months ago
VNRX......................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
VNRX new 52 week low
πŸ‘οΈ0
glenn1919 glenn1919 10 months ago
VNRX................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783
πŸ‘οΈ0
Disquisition Disquisition 10 months ago
HORRENDOUS DUMPING
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
VNRX new 52 week low
πŸ‘οΈ0
budgetthis budgetthis 1 year ago
Give me $2.50 !!

$$ VNRX $$
πŸ‘οΈ0
Happycoins Happycoins 4 years ago
Seems like very bad news stocks getting hammard premarket.
πŸ‘οΈ0
whytestocks whytestocks 4 years ago
News: $VNRX Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test

AUSTIN, Texas , July 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company applying its Nu.Q™ Nucleosomics™ technology to develop simple, cost effective blood-based tests for cancer and other diseases, today...

In case you are interested VNRX - Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $VNRX Video Chart 07-14-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
maljo maljo 4 years ago
good news today, hope it runs to $5
πŸ‘οΈ0
rodman rodman 4 years ago
Whatever happened to the supposed out of the box blood test for a colonoscopy procedure replacement. This company has been a funding animal like a pac-man eating of the $$$$$$$$$'s!
Geez!
rod
πŸ‘οΈ0
XenaLives XenaLives 4 years ago
I suspect the patent is about more than COVID...


Introduction
Neutrophils are the most abundant leukocytes in mammals and, as a first line of defense against microbes, they play crucial roles in innate immune responses. The homeostasis of neutrophils is maintained by balancing their short lifespan in the circulation with their regulated release from the bone marrow. Neutrophils have various types of granules, containing hundreds of proteins. These include bactericidal proteins, some of them with important effects on innate and adaptive immune responses, such as a-defensins, the cathelicidin human cationic antimicrobial protein of 18 kDa, and lactoferrin, among others. LL-37, a proteolytic product of human cationic antimicrobial protein of 18 kDa, has important chemotactic and immunostimulatory effects, as discussed below (1).

The mechanisms used by neutrophils to eliminate microbes include phagocytosis, generation of reactive oxygen species (ROS), and the release of microbicidal molecules from granules (degranulation). In 2004, another distinct antimicrobial activity was described: neutrophils extrude a meshwork of chromatin fibers that are decorated with granule-derived antimicrobial peptides and enzymes such as neutrophil elastase (Fig. 1), cathepsin G, and myeloperoxidase (MPO) (2). These structures, called neutrophil extracellular traps (NETs), represent an important strategy to immobilize and kill invading microorganisms. The NET scaffold consists of chromatin fibers with a diameter of 15–17 nm; DNA and histones represent the major NET constituents (2). Mass spectrometry has identified various additional proteins associated with NETs, including components from various types of granules. Although conserved proteins are found in extracellular trap fractions, it is still unclear whether the peptide composition of these structures may vary depending on the specific stimulus that promotes NET formation (3, 4).

Cont..


https://www.jimmunol.org/content/189/6/2689.long
πŸ‘οΈ0
XenaLives XenaLives 4 years ago
4/23/20 - Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies

AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, using its propriety Nu.QTM platform. The goal of the test is to provide early insight into which patients may require higher levels of monitoring including hospitalization and critical care resources, versus those who will not develop serious symptoms. Preliminary studies of patients with COVID-19 infection are now underway in hospitals in Belgium and Germany with results expected this quarter.

Full PR:
https://finance.yahoo.com/news/volition-files-patent-nu-q-123000672.html



πŸ‘οΈ0
XenaLives XenaLives 4 years ago
Volition Video Gallery:

https://volition.com/press-room/video-gallery
πŸ‘οΈ0
XenaLives XenaLives 4 years ago
More eavesdropping:



gordoncamelion wrote on 20.05.20 11:13:27 Entry No. 1.763 (63,747,802) The results from the large lung cancer study should come in Q2 2020. Here are the topics that will come this year. Upcoming Milestones We expect the company to accomplish some of the near-term milestones below: ? Q2 Clinical performance data from individual assays and in the panel combinations across the range of cancers ? Q2 / 3 Clinical data from COVID-19 studies currently underway ? Advance large-scale colorectal and lung cancer trials in Europe, Asia and the US ? Determine the level of tumor associated nucleosomes using mass spectrometry and identify NEW biomarker targets ? Q2 Utilize Nu.Q sequencing to identify tumor of origin and specific mutations ? Q3 Utilize in conjunction with Nu.Q immunoassay approach to enhance performance ? Q4 Launch Nu. Q Vet




https://www.wallstreet-online.de/diskussion/1275261-1761-1770/bluttest-krebserkennung-valitionrx-was
πŸ‘οΈ0
XenaLives XenaLives 4 years ago
Eavesdropping:


Labsolute wrote on 21.05.20 17:25:37 Entry No. 1.785 (63.763.840) Reply to entry no .: 63.763.585 by tycoon111 am 05/21/20 16:55:36 I am optimistic from the bottom up and may be concerned with my investments, maybe that's the reason And: the burn rate is great, nothing is too high !! Capital increases are also absolutely normal for such companies. Volition has never had any problems getting fresh cash in the past and has always been supported by the state. You can not be blamed for burning the shareholders' money senselessly! And slowly what needs to be monetized is your opinion as so I take on young impatient small shareholders. I see the data that was published a week ago and I know that such a diagnosis no other company in the world can - not at Stage1 and not at the price and time required. And in my opinion it will stay that way for a long time! I do not know whether the price climbs up or down as your question was - but I see a ridiculous market capitalization which can only increase tenfold in the short term (vet / Lung china / COVID) with just one successful piece of the puzzle and on the other hand I see a stable balance sheet a lot of cash and competitors who all still need a lot of time! So an excellent change risk ratio, even if small cap very risky!





Labsolute wrote on 23.05.20 14:18:01 Entry No. 1.789 (63.779.455) no topic - welcome to high risk - high reward. You have to get along with the Vola - especially difficult as an ETF investor. Always think of fear vs greed and rationally rethink everything in difficult phases. We are in a wild market phase: from V-recovery to deepest depression, everything is in the room - if you have already felt uncomfortable, rethink the position size. Otherwise there is now more than enough cash in the company to survive this phase and we can look forward to further data and news this year. Reynolds directly secured a small package for $ 2.75. Think that calms many people again.



https://www.wallstreet-online.de/diskussion/1275261-1781-1790/bluttest-krebserkennung-valitionrx-was
πŸ‘οΈ0
XenaLives XenaLives 4 years ago
EIGHT CORPORATION LIMITED REPORTS 23.8% STAKE IN VOLITIONRX LTD AS OF MAY 29 - SEC FILING


HEALTHCAREJUNE 2, 2020 / 4:08 PM / UPDATED 13 HOURS AGO
BRIEF-Eight Corporation Limited Reports 23.8% Stake In Volitionrx Ltd As Of May 29
1 MIN READ

June 2 (Reuters) - VolitionRX Ltd:

* EIGHT CORPORATION LIMITED REPORTS 23.8% STAKE IN VOLITIONRX LTD AS OF MAY 29 - SEC FILING

* EIGHT CORPORATION LTD-ON MAY 29, CONTACTED VOLITIONRX’S BOARD TO REQUEST EXPANSION OF BOARD AS WELL AS APPOINTMENT OF 3 DIRECTORS SELECTED BY THEM

* EIGHT CORPORATION LTD - REQUESTED VOLITIONRX’S BOARD FORM A COMMITTEE TO EVALUATE, AMONG OTHER THINGS, BUSINESS STRATEGY AND SUCCESSION PLANS

* EIGHT CORPORATION LTD - HAD PREVIOUSLY REPORTED 29.2% STAKE IN VOLITIONRX AS OF MAY 7 Source text: (bit.ly/2Y8YnEv) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.




https://uk.reuters.com/article/brief-eight-corporation-limited-reports/brief-eight-corporation-limited-reports-238-stake-in-volitionrx-ltd-as-of-may-29-idUKFWN2DF0O6
πŸ‘οΈ0
XenaLives XenaLives 4 years ago
Epigenetic change has also compromised our immune systems. I believe this is the primary reason why seniors are dying of COVID in the nursing homes.

Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference

https://volition.com/press-room/press-releases/volition-announces-cameron-reynolds-president-and-chief-executive-officer-invited-as-presenter-at-maxims-covid-19-virtual-conference
πŸ‘οΈ0
XenaLives XenaLives 4 years ago
Epigenetics is an issue in much more than cancer.

I suspect that this is just an initial focus for this company but will have to do more research.
πŸ‘οΈ0
XenaLives XenaLives 4 years ago
Only 8% insty ownership but this bears looking into:


2020-05-07 13D/A Eight Corp Ltd 12,045,332 29.20
2019-08-01 13D Cotterford Co Ltd 12,041,570 29.30
2019-02-25 13G/A Hever Investments Ltd 11,877,476 29.40
2019-02-14 13G/A Lagoda Investment Management, L.P. 1,643,714 4.70
2019-02-11 13D/A Innes Guy Archibald 1,875,701 5.30
2018-11-09 13D/A Faulkes Martin Charles 1,977,284 5.60
2018-11-09 13D/A Reynolds Cameron John 2,562,967 7.20
2017-02-08 13G/A MANCHESTER MANAGEMENT CO LLC 1,212,159 4.60
2016-12-29 13D Hunt David 63,440,000 62.30
πŸ‘οΈ0
XenaLives XenaLives 4 years ago
Intriguing stock, from the Ibox:


Nucleosomics® Accessing the Epigenome



The company’s NuQ® range of research uses only epigenetic research tools, and is available to life science researchers in a familiar and accessible format – the simple immunoassay.
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX this little bull is about to blow up. The cancer play of the year
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $VNRX Video Chart 09-25-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $VNRX Video Chart 09-24-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX amazing strength!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX OMG look at her run!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX here she goes...this monster is going to blow up!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX boom...a monster!!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX boom and halt!!! come on baby!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX boom Out of the gate!
πŸ‘οΈ0
Golden Cross Golden Cross 5 years ago
VNRX Daily Chart

πŸ‘οΈ0
Golden Cross Golden Cross 5 years ago
96% Technical BUY Rating

https://www.barchart.com/stocks/quotes/VNRX/opinion
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX about to become a low float monster. Just wait for the volume to really kick in
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX wowza what a close..morning call went out!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX look at her go..oh my lord!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX friday monster surge...this one is gonna be fun!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
Here we go...VNRX the next bio beast!!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX new nasy jazzy bio wonder play...watch this beast take off!!
πŸ‘οΈ0
whytestocks whytestocks 5 years ago
News: $VNRX Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

AUSTIN, Texas , Sept. 17, 2019 /PRNewswire/ --  VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.Q TM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin....

Find out more VNRX - Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
πŸ‘οΈ0
pottsville pottsville 5 years ago
Not today tho.. Chuckle
πŸ‘οΈ0
pottsville pottsville 5 years ago
I do like what I'm seeing here
πŸ‘οΈ0
whytestocks whytestocks 5 years ago
News: $VNRX Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock

AUSTIN, Texas , July 24, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a further strengthening of its balance sheet with an existing investor exercising the balance of its warrant to purchase $4.8 million in aggregate amount of shar...

Read the whole news Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock
πŸ‘οΈ0
whytestocks whytestocks 5 years ago
News: $VNRX VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

AUSTIN, Texas , July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately $1.4 million from the Walloon Region, B...

In case you are interested VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding
πŸ‘οΈ0
wiltonio wiltonio 6 years ago
Cotterford Co Ltd has filed a new 13G, reporting 29.4% ownership in $VNRX - https://fintel.io/so/us/vnrx and https://fintel.io/i/cotterford
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock